CC Bio

1 known investors

CC Bio develops synthetic biology-based therapeutics to treat microbiome-related diseases by engineering and editing the microbiome with precision. The company uses its proprietary Zeus platform to discover and optimize first-in-class treatments for patients seeking alternatives to antibiotics.

BiotechHealthtechMedical Devices